The socalled pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the process of drug synthesis. These chemicals, which do not require a pharmaceutical manufacturing license, can be produced in ordinary chemical plants and can be used in the synthesis of medicines as long as they reach a certain grade.

After nearly 30 years of development, the pharmaceutical intermediates industry in China has developed from a small branch of chemical industry to a new industry with an output value of billions of yuan. In the early stage of industry development, due to small investment and high rate of return, pharmaceutical intermediates enterprises mushroomed, especially in Huangyan, Taizhou, Jintan, Shijiazhuang, Jinan, northeast China and other areas with f***orable conditions for the development of pharmaceutical intermediates, especially rapid development.

At present, the limited production of new drugs on the market, resulting in the pharmaceutical intermediates industry new product development is more and more difficult, the competition of traditional products is more and more fierce, pharmaceutical intermediates industry profits rapidly decline.

1, improve technology, cost s***ing pharmaceutical intermediates process route is long, reaction steps, solvent use is large, great potential for technical improvement. For example, raw materials of lower value can be used to replace raw materials of higher value, such as substitute liquid bromine in the production of aminotaxime acid, ammonium thiocyanate in the production of potassium thiocyanate (sodium), etc. A single solvent was used to replace the different solvents in the reaction process and the alcohols generated by hydrolysis of ester products were recovered.

2, the formation of their own characteristic products industry influence.

3. Extend the industrial chain upward and downstream. Turn the main raw materials we use into our own production, which can further reduce the cost. Further down the line is the direct synthesis of pharmaceutical intermediates into apis, which can further increase the added value of the product and sell the product directly to pharmaceutical companies. However, the downstream extension requires large investment, high production technology requirements, and a good relationship with the manufacturers of active substances.